George Grunberger, MD
Endocrinology, Diabetes & Metabolism · Bloomfield Hills, MINPI 1477558450
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $709,552 of the $930,769 with a category attached, or 76.2%. 60 manufacturers reported payments, led by Lilly USA, LLC at 48.6% of the total. Among endocrinology, diabetes & metabolism clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,611 payments — averaging $577.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$452K
- Novo Nordisk$113K
- Abbott$77K
- Sanofi-aventis U.S. LLC$70K
- Nevro Corp.$45K
- Lifescan, Inc.$21K
- plus $152K from 54 others
Across 60 payments — averaging $16,994 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$978K
- Novo Nordisk AS$32K
- Lifescan, Inc.$5K
- Eli Lilly$4K
- Sanofi-aventis U.S. LLC$750
- Merck$171
What the payments were for
- Consulting fees$111,65612%
- Speaking & faculty fees$709,55276%
- Travel & lodging$75,9888%
- Food & beverage$33,2614%
- Education$3120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$196,311
- TRULICITY$122,608
- Ozempic$44,330
- TZIELD$41,061
- Omnia$39,820
- JARDIANCE$36,147
- RYBELSUS$30,734
- FREESTYLE LIBRE 3$30,445
- FreeStyle Libre Pro$23,772
- SOLIQUA 100/33$23,474
- FreeStyle Libre$20,554
- Tresiba$18,695
- Victoza$14,699
- CeQur Simplicity$14,552
- AFREZZA$14,255
- Eversense$9,900
- FARXIGA$9,659
- GVOKE PFS$9,058
- INVOKANA$8,791
- HUMULIN$7,500
How this compares
$930,769 in reported general payments places this provider in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 200 | $302,042 |
| Tresiba Flextouch U-200Insulin Degludec | 62 | $147,423 |
| OzempicSemaglutide | 82 | $136,373 |
| JardianceEmpagliflozin | 76 | $112,113 |
| FarxigaDapagliflozin Propanediol | 79 | $94,488 |
| TrulicityDulaglutide | 39 | $74,033 |
| RybelsusSemaglutide | 28 | $51,235 |
| InvokanaCanagliflozin | 23 | $37,919 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $32,695 |
| Novolog FlexpenInsulin Aspart | 59 | $31,130 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $29,413 |
| JanuviaSitagliptin Phosphate | 23 | $24,534 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $22,430 |
| Humalog Kwikpen U-100Insulin Lispro | 28 | $17,788 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $15,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog | $452,233 | $388,401266 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp | $113,077 | $200,548124 claims |
| Boehringer IngelheimJardiance | $9,907 | $112,11376 claims |
| AstraZenecaFarxiga | $10,189 | $94,48879 claims |
| MerckJanuvia, Janumet | $1,342 | $39,83737 claims |
| Johnson & JohnsonInvokana | $9,161 | $37,91923 claims |
| AbbVieSynthroid | $46 | $1,41211 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $88 | $49651 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Bloomfield Hills
- Anjana MyneniBloomfield Hills$14K
- Lowell SchmeltzFarmington Hills$1.3M
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Eric LangerSterling Heights$213K
- Ashish VermaShelby Twp$179K
- Kara HoisingtonLansing$178K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.